Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide/north-carolina/charlotte
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Charlotte, NC

Verified Semaglutide providers in Charlotte, NC. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
46
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: North Carolina
39 of 39 shown

Find a Semaglutide provider in North Carolina.

Every entry is checked against the NPI registry and the North Carolina medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by North Carolina city · /semaglutide/north-carolina/{city}
Greensboro
32 →
Durham
39 →
Raleigh
35.78°N
40 →
§ 03Getting Semaglutide in Charlotte
39 providers · Charlotte, NC

How to get Semaglutide in Charlotte.

39 GLP-1 prescribers and 7 local resource types are on record for Charlotte, plus 3 nearby towns in the directory.

Prescribers in Charlotte
39 prescribers
39 GLP-1 prescribers in Charlotte, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (15) and Internal Medicine (7). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Greensboro (32 providers), Durham (39 providers) and Raleigh (40 providers).
Around the prescription in Charlotte
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Charlotte.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in North Carolina

Diagnosed diabetes reaches 11% of adults in North Carolina.

of North Carolina adults have obesity
34.5%
diagnosed diabetes
11%

Age-adjusted estimates for North Carolina, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losshow tirzepatide titration works
§ 05Support around Semaglutide in Charlotte
6 dietitians

The prescription is one part. Here is the rest, in Charlotte.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Charlotte, NC, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Samara Abbott, RD
RD
Registered dietitian
2820 Selwyn Ave Ste 745
Call 980-349-7763NPI 1942754031
Mark Abesamis
RD
Registered dietitian
2400 Yorkmont Rd
Call 877-311-4747NPI 1730667825
Rachel Adamkowski, RD, LDN
RD
Registered dietitian
5355 Pinehurst Park Dr Apt 207
Call 919-376-5692NPI 1528825080
Praja Adhikari
RD
Registered dietitian
15015 Lancaster Hwy Ste 200
Call 980-202-7980NPI 1265155071
Cory Akers
RD
Registered dietitian
6371 Jessie Ln
Call 336-740-9060NPI 1033094339
Amber Allen, RD
RD
Registered dietitian
1001 Blythe Blvd Ste 200
Call 704-381-8840NPI 1851275002

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Barbara Bapst, MPH, RD, LDN
NUTRITIONIST
Nutritionist
2147 Mount Holly Huntersville Rd
Call 704-398-1864NPI 1285697169
Annalise Brawley
NUTRITIONIST
Nutritionist
2125 Southend Dr Apt 109
Call 704-614-0513NPI 1346197647
Devin Buss, MPH
NUTRITIONIST
Nutritionist
6633 Fairview Rd
Call 704-366-1264NPI 1326662511
Jessica Crenshaw, MS, CNS, LN
NUTRITIONIST
Nutritionist
10400 Mallard Creek Rd Ste 340
Call 704-549-9550NPI 1942192547
Kelli Davenport, MS, RD, LDN
NUTRITIONIST
Nutritionist
600 Moye Blvd
Call 252-744-1959NPI 1073887956
Jessica Demczar, LN, CNS, MS
NUTRITIONIST
Nutritionist
3020 Cullman Ave Apt 302
Call 845-489-7631NPI 1033973763
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in North Carolina

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in North Carolina
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in North Carolina
Clinics running GLP-1 programs, telehealth & in-person.
Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Semaglutide in Alabama→Semaglutide in Alaska→Semaglutide in Arizona→Semaglutide in Arkansas→Semaglutide in California→Semaglutide in Colorado→Semaglutide in Connecticut→Semaglutide in Delaware→Semaglutide in Florida→Semaglutide in Georgia→Semaglutide in Hawaii→Semaglutide in Idaho→Semaglutide in Illinois→Semaglutide in Indiana→Semaglutide in Iowa→Semaglutide in Kansas→Semaglutide in Kentucky→Semaglutide in Louisiana→Semaglutide in Maine→Semaglutide in Maryland→Semaglutide in Massachusetts→Semaglutide in Michigan→Semaglutide in Minnesota→Semaglutide in Mississippi→Semaglutide in Missouri→Semaglutide in Montana→Semaglutide in Nebraska→Semaglutide in Nevada→Semaglutide in New Hampshire→Semaglutide in New Jersey→Semaglutide in New Mexico→Semaglutide in New York→Semaglutide in North Carolina→Semaglutide in North Dakota→Semaglutide in Ohio→Semaglutide in Oklahoma→Semaglutide in Oregon→Semaglutide in Pennsylvania→Semaglutide in Rhode Island→Semaglutide in South Carolina→Semaglutide in South Dakota→Semaglutide in Tennessee→Semaglutide in Texas→Semaglutide in Utah→Semaglutide in Vermont→Semaglutide in Virginia→Semaglutide in Washington→Semaglutide in West Virginia→Semaglutide in Wisconsin→Semaglutide in Wyoming→
Related GLP-1 research
hair shedding during weight loss
Why rapid loss can shed hair, and what helps it regrow.
the GLP-1 timeline to appetite suppression
When appetite changes show up, and when the weight curve usually follows.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Semaglutide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]